Sugi Predict

Sugi Predict / Compounds / SCHEMBL30924005

SCHEMBL30924005

SCHEMBL30924005

CC(C)(C)OC(=O)N1C[C@@H](NS(C)(=O)=O)C(F)(F)[C@H]1CCO

nearest known ligand 0.36

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ HCRTR2 O43614 1/20 0.34
▸ NR1H2 P55055 11/20 0.33
▸ HSD11B1 P28845 1/20 0.32
▸ SCN9A Q15858 1/20 0.31
▸ NR1H3 Q13133 9/20 0.31
▸ RXRA P19793 7/20 0.31
▸ F13A1 P00488 1/20 0.31
▸ TGM2 P21980 1/20 0.31
▸ TGM1 P22735 1/20 0.31
▸ PTPN1 P18031 1/20 0.30
▸ KDM1A O60341 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30923988 0.91 NR1H2 (0.36) HCRTR2NR1H2HSD11B1SCN9ANR1H3
SCHEMBL30924012 0.90 NR1H2 (0.34) NR1H2HSD11B1F13A1TGM2TGM1
SCHEMBL30923983 0.88 KDM1A (0.33) HCRTR2NR1H2HSD11B1SCN9AKDM1A
SCHEMBL30923940 0.85 HCRTR2 (0.34) HCRTR2NR1H2SCN9ANR1H3PTPN1
SCHEMBL30924050 0.78 HCRTR2 (0.42) HCRTR2NR1H2NR1H3PTPN1
SCHEMBL30924048 0.78 HCRTR2 (0.42) HCRTR2NR1H2NR1H3PTPN1
SCHEMBL30923972 0.75 NR1H2 (0.34) NR1H2NR1H3
SCHEMBL30923970 0.75 NR1H2 (0.34) NR1H2NR1H3
SCHEMBL30954990 0.71 NR1H2 (0.38) NR1H2SCN9A
SCHEMBL30954988 0.71 NR1H2 (0.38) NR1H2SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122071471-A Heterocyclic compounds 武田药品工业株式会社 2026-05-22 — — CN disclosed
CN-122010946-A Heterocyclic compounds 武田药品工业株式会社 2026-05-12 — — CN disclosed
CN-122010945-A Heterocyclic compounds 武田药品工业株式会社 2026-05-12 — — CN disclosed
US-12534471-B2 Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2026-01-27 — — US disclosed
EP-4612145-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2025-09-10 — — EP disclosed
US-20240317765-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-09-26 — — US disclosed
US-20240174677-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-05-30 — — US disclosed
WO-2024095133-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317765-A1 HETEROCYCLIC COMPOUND HCRTR2, HCRTR1, NPY2R HCRTR2 1/4885NR1H2 170/4885HSD11B1 555/4885
US-20240174677-A1 HETEROCYCLIC COMPOUND HCRTR2, HCRTR1, NPY2R HCRTR2 1/4885NR1H2 170/4885HSD11B1 555/4885
US-12534471-B2 Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof HCRTR2, HCRTR1, NPY1R HCRTR2 1/4885NR1H2 79/4885HSD11B1 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.